Alzheimer’s Disease Workgroup (ALZ)

Workgroup Chairs: Danielle Posthuma and Ole Andreassen



Alzheimer’s disease (AD) is the most common neurodegenerative disease and is expected to bring along large medical and economic problems with the aging of the worldwide population. To improve the current treatment of AD we require an advanced understanding of underlying biological mechanisms that are involved in the initiation of pathological processes leading to clinical AD. Genetics might shed important light on this subject, as it allows to objectively (without assumptions about underlying functional mechanisms involved in the disease) obtain novel knowledge on the biological origin of the disease.

Genetic dissection of complex diseases (like AD) require very large sample sizes. This in turn requires the careful analysis of as many samples as possible. As part of the Psychiatric Genomics Consortium, we published our first study1 in Nature Genetics this year with the Alzheimer’s working group (PGC-ALZ). To continue our search for novel genetic factors for AD we aim to add a substantial number of patients in a second wave of PGC-ALZ, by initiating various new collaborations.


The main goal of our research is to identify novel genetic risk factors for Alzheimer’s disease risk, which we anticipate to contribute to better understanding of the underlying disease pathology that is required for the development of improved treatment in the future.

Select Publications
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk.Nat Genet. 2019 Mar;51(3):404-413. doi: 10.1038/s41588-018-0311-9. Epub 2019 Jan 7